Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
Indolent B-cell Non-Hodgkin's Lymphoma
DRUG: ME-401
Objective response rate (ORR), ORR is measured as the proportion of subjects achieving the best response rating of complete response (CR) or partial response (PR) prior to first progressive disease (PD)., Up to approximately 2 years
Efficacy of ME-401 as assessed by the duration of response (DOR), Up to approximately 4 years|Efficacy of ME-401 as assessed by the progression-free survival (PFS), Up to approximately 4 years|Efficacy of ME-401 as assessed by CR, Up to approximately 4 years|Efficacy of ME-401 as assessed by the Time to treatment failure (TTF), Up to approximately 4 years|Efficacy of ME-401 as assessed by the objective response rate (ORR), Up to approximately 4 years|Safety of ME-401 as assessed by the number of participants with treatment-emergent adverse events (TEAEs), Up to approximately 4 years|Safety of ME-401 as assessed by the time to occurrence of adverse event of special interest (AESI), Up to approximately 4 years|Plasma concentration level of ME-401, Up to approximately 4 years
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.